Clinical trial · Interventional
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis
Multicenter Prospective Pilot Study Investigating Pathophysiology, Diagnostic and Therapeutic Strategies of Hepatosplenic Candidiasis
NCT01916057CI-TRIAL-00094712CANHPARIcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Disseminated Candidiasis | — | UNRESOLVED | — |
| Hematological Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Hematopoietic Stem Cell Transplantation | — | UNRESOLVED | — |
| Invasive Fungal Disease | — | UNRESOLVED | — |
| Neutropenia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FDG PET Scan | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 18F-FDG PET Scan
- description
- 18F-FDG PET Scan at Day 0 and M3
- interventionNames
- Device: 18F-FDG PET Scan
Primary outcomes (1)
- measure
- Global response to therapy
- timeFrame
- at month 3
- description
- Clinical assessment (no fever) and PET scan assessment (intensity of liver and/or spleen lesions)
Secondary outcomes (8)
- measure
- 18F-FDG PET scan and RMI usefulness in initial diagnosis
- timeFrame
- at month 3
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Patients' inclusion criteria: * Adults aged ≥18 years-old * Hospitalized for hematological malignancy or hematopoietic stem cell transplantation * Recent (\>2months), prolonged (\>10 days), profound (\>100 PMN/mm3), feverish neutropenia * Suspected hepatosplenic candidiasis (typical small nodular lesions on abdominal RMI or CT) Patients' exclusion criteria: \- hepatosplenic lesions of other proven origin Patients' non-inclusion criteria: * Life expectancy \>3 months * Pregnancy * HIV infection * Hepatic biopsy within 3 weeks before 18F-FDG PET scan
References
Publications (2)
- RESULTRammaert B, Maunoury C, Rabeony T, Correas JM, Elie C, Alfandari S, Berger P, Rubio MT, Braun T, Bakouboula P, Candon S, Montravers F, Lortholary O. Does 18F-FDG PET/CT add value to conventional imaging in clinical assessment of chronic disseminated candidiasis? Front Med (Lausanne). 2022 Dec 20;9:1026067. doi: 10.3389/fmed.2022.1026067. eCollection 2022. PMID 36606049
- RESULTCandon S, Rammaert B, Foray AP, Moreira B, Gallego Hernanz MP, Chatenoud L, Lortholary O. Chronic Disseminated Candidiasis During Hematological Malignancies: An Immune Reconstitution Inflammatory Syndrome With Expansion of Pathogen-Specific T Helper Type 1 Cells. J Infect Dis. 2020 May 11;221(11):1907-1916. doi: 10.1093/infdis/jiz688. PMID 31879764